Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition

Stock Track

01/07

Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.

The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1118501726"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118501726\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118501726?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 17:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118501726","market":"sg","top_or_hot":-1,"title":"Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition","media":"Stock Track","content":"<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.</p><p>The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ventyx Biosciences Soars 69.25% in Pre-Market as Eli Lilly Eyes $1 Billion Acquisition\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-01-07 17:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.</p><p>The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTYX","symbol_name":"Ventyx Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1118501726","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118501726","pubTimestamp":1767777178,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTYX":"Ventyx Biosciences, Inc."},"translate_title":"个股追踪|Ventyx Biosciences盘前大涨69.25%礼来有意10亿美元收购","themeId":"d9d938951d4e1d58a135a999ef2d5d12","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":1},"content_text":"Ventyx Biosciences, Inc. (NASDAQ: VTYX) saw its stock surge 69.25% in pre-market trading following reports that Eli Lilly is in advanced talks to acquire the company for over $1 billion. The potential deal would significantly boost Lilly's portfolio with Ventyx's pipeline of drugs targeting inflammatory bowel diseases like Crohn's disease and ulcerative colitis, as well as treatments for Parkinson's disease and cardiovascular conditions linked to obesity.The Wall Street Journal first reported the acquisition talks, citing people familiar with the matter. Ventyx's experimental drugs, particularly those in mid-stage clinical trials, have attracted significant interest from large pharmaceutical companies, making it a strategic target for Eli Lilly. The market reacted swiftly to the news, driving Ventyx's stock price to new highs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}